Abstract
It has been known that chronic liver treatments interfere with blood glucose metabolism. It was recognized that diabetes mellitus among chronic hepatitis C was greater in other types of chronic liver diseases. Hepatitis C directly promotes insulin resistance through the proteosomal degradation of insulin resistance substrate. It suppressed hepatocyte glucose uptake through down-regulation of surface expression of glucose transporter. Long-term exposure to cytokine over expression seems to be cytotoxic to both beta cells of the pancreas and to hepatocytes. Elevated tumor necrosis factor-a, or its neutralization, increased insulin sensitivity. Interferon-a may also elevate the serum level of interleukin-1 which is cytotoxic to pancreatic islet cells. Both Diabetes mellitus and resistance to interferon-a therapy are abnormally mediated by over-expression of suppressor of cytokine signaling-1 in hepatocytes of chronic hepatitis C patients.
Conclusion: These data suggest that interferon-a therapy should be administered with caution in patients showing any predisposition to Diabetes mellitus. Anti inflammatory therapy is critically recommended as a protector against disease development due to cytokine mediated Diabetes mellitus during hepatitis C therapy, since inflammation seems to be a main candidate to interferon suspected diabetogenesis.
Keywords: Diabetes mellitus, HCV, inflammatory mediators, molecular mediators, anti inflammatory.
Current Diabetes Reviews
Title:Underlying Pathways for Interferon Risk to Type II Diabetes Mellitus
Volume: 9 Issue: 6
Author(s): Nabil Abdel-Hamid, Taghreed Al Jubori, Amaal Farhan, Mariam Mahrous, Adel Gouri, Ezzat Awad and Johannes Breuss
Affiliation:
Keywords: Diabetes mellitus, HCV, inflammatory mediators, molecular mediators, anti inflammatory.
Abstract: It has been known that chronic liver treatments interfere with blood glucose metabolism. It was recognized that diabetes mellitus among chronic hepatitis C was greater in other types of chronic liver diseases. Hepatitis C directly promotes insulin resistance through the proteosomal degradation of insulin resistance substrate. It suppressed hepatocyte glucose uptake through down-regulation of surface expression of glucose transporter. Long-term exposure to cytokine over expression seems to be cytotoxic to both beta cells of the pancreas and to hepatocytes. Elevated tumor necrosis factor-a, or its neutralization, increased insulin sensitivity. Interferon-a may also elevate the serum level of interleukin-1 which is cytotoxic to pancreatic islet cells. Both Diabetes mellitus and resistance to interferon-a therapy are abnormally mediated by over-expression of suppressor of cytokine signaling-1 in hepatocytes of chronic hepatitis C patients.
Conclusion: These data suggest that interferon-a therapy should be administered with caution in patients showing any predisposition to Diabetes mellitus. Anti inflammatory therapy is critically recommended as a protector against disease development due to cytokine mediated Diabetes mellitus during hepatitis C therapy, since inflammation seems to be a main candidate to interferon suspected diabetogenesis.
Export Options
About this article
Cite this article as:
Abdel-Hamid Nabil, Jubori Al Taghreed, Farhan Amaal, Mahrous Mariam, Gouri Adel, Awad Ezzat and Breuss Johannes, Underlying Pathways for Interferon Risk to Type II Diabetes Mellitus, Current Diabetes Reviews 2013; 9 (6) . https://dx.doi.org/10.2174/15733998113096660080
DOI https://dx.doi.org/10.2174/15733998113096660080 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Platelet Hyperreactivity and Stent Thrombosis in Patients Undergoing Coronary Stenting
Current Vascular Pharmacology Biochemical Changes Evidenced in Alzheimer's Disease: A Mini-Review
Letters in Drug Design & Discovery Anti-HCV Prevalence among Diabetic and Non-Diabetic Egyptian Children
Current Diabetes Reviews Comparative Effectiveness of Pioglitazone and Rosiglitazone in Type 2 Diabetes, Prediabetes,and the Metabolic Syndrome: A Meta-Analysis
Current Diabetes Reviews Vitamin D is Related to Markers of Vulnerable Plaque in Acute Myocardial Infarction
Current Vascular Pharmacology The Efficacy of Psychological Therapies for Specific Phobias in Adults and Some Unanswered Questions
Current Psychiatry Reviews CoMFA, CoMSIA and HQSAR Analysis of 3-aryl-3-ethoxypropanoic Acid Derivatives as GPR40 Modulators
Current Drug Discovery Technologies Morphology of Atherosclerotic Plaque: Its Feature by Imaging Study
Current Pharmaceutical Design Cell-free DNA: Characteristics, Detection and its Applications in Myocardial Infarction
Current Pharmaceutical Design PCSK9 Inhibitors for the Management of Dyslipidemia in People with Type 2 Diabetes: How Low is Too Low?
Current Pharmaceutical Design The Benefits of Exercise and Metabolic Interventions for the Prevention and Early Treatment of Alzheimer's Disease
Current Alzheimer Research The Therapeutic Potential of Allosteric Ligands for Free Fatty Acid Sensitive GPCRs
Current Topics in Medicinal Chemistry Drug-induced Cholelithiasis
Current Reviews in Clinical and Experimental Pharmacology Towards Standardized Stem Cell Therapy in Type 2 Diabetes Mellitus: A Systematic Review
Current Stem Cell Research & Therapy Novel Cardiovascular Risk Factors and Macrovascular and Microvascular Complications of Diabetes
Current Drug Targets Patent Selection
Recent Patents on Engineering Peptides, Proteins and Peptide/Protein-Polymer Conjugates as Drug Delivery System
Protein & Peptide Letters Fetal and Obstetric Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Cytochromes P450 in the Bioactivation of Chemicals
Current Topics in Medicinal Chemistry In vitro Generated Mesenchymal Stem Cells: Suitable Tools to Target Insulin Dependent Diabetes Mellitus?
Current Stem Cell Research & Therapy